ArticleCirculation research2024
Indole-3-Propionic Acid Protects Against Heart Failure With Preserved Ejection Fraction.
Article in Circulation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06645535 (The Role and Mechanism of Gut Microbiota and Metabolites in Heart Failure With Preserved Ejection Fraction), which is not on this map. Cited by 92 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Role and Mechanism of Gut Microbiota and Metabolites in Heart Failure With Preserved Ejection Fraction
Who cites it
92 citing papers in PubMed, 102 citations in OpenAlex.
- Machine learning identifies microbiome and clinical predictors of sustained weight loss following prolonged fasting.Genome medicine · 2026Trial
- Skeletal muscle metabolomic markers underlying the enhanced exercise-induced hypertrophy response to resistance training in older adults.GeroScience · 2026Article
- Review
- Mechanisms of gut microbiota metabolite-mediated gut-heart Axis in heart failure: An integrative study based on network pharmacology.American heart journal plus : cardiology research and practice · 2026Article
- Mesenteric denervation ameliorates post‑infarction heart failure alongside alterations in the gut-nerve-microbiota axis.Basic research in cardiology · 2026Article
- The Gut Microbiota-Metabolite-Host Axis in Cardiometabolic Diseases: Bridging Bench to Bedside.Cardiovascular drugs and therapy · 2026Review
- Gut microbiome shifts in chronic systolic heart failure are associated with disease severity and clinical improvement.Nature cardiovascular research · 2026Article
- Gut Microbiota-Derived Indole-3-Propionic Acid Alleviates Diabetic Osteoporosis Through Nrf2-Mediated Ferroptosis Suppression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Multi-omics-driven precision medicine.iMeta · 2026Review
- Cardiac fibroblast diversity in HFpEF: states, niches, interorgan drivers and targets.Nature reviews. Cardiology · 2026Review
- The gut microbiome and allograft outcomes: implications for heart transplantation.The Journal of clinical investigation · 2026Review
- The maternal gut microbiota influences myocardial maturation and diastolic function of offspring in mice.Science China. Life sciences · 2026Article
- Effects of Low Methionine Intake on Gastric Ulcer in Patients and Mice: Role of the NNMT Pathway.Molecular nutrition & food research · 2026Article
- Decoding the Gut-Fat-Heart Axis: From Molecular Communication Networks to Clinical Translation Strategies.International journal of molecular sciences · 2026Review
- Tryptophan Metabolism in Cardiometabolic Diseases: Focus on the Kynurenine Pathway.International journal of molecular sciences · 2026Review
- Mass spectrometry-based metabolomics for studying gut microbiota-derived metabolites in biological samples.Journal of food and drug analysis · 2026Review
- Indoleacrylic acid mitigates vascular rarefaction and enhances ischemia-induced neovascularization in aging via APLNR signaling.Acta pharmacologica Sinica · 2026Article
- Review
- Probiotics and Postbiotics in Life-Style Disease Management: A Comprehensive Review on the Technologies in the Era of Omics and Artificial Intelligence.Probiotics and antimicrobial proteins · 2026Review
- Bile Acids and the Gut-X Axis: TCM-Mediated Systemic Protection and Therapeutic Opportunities for Multi-Organ Diseases.Metabolites · 2026Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
16 authors at 12 institutions in 5 countries.
Funding
Abstract
backgroundHeart failure with preserved ejection fraction (HFpEF) is a common but poorly understood form of heart failure, characterized by impaired diastolic function. It is highly heterogeneous with multiple comorbidities, including obesity and diabetes, making human studies difficult.
methodsMetabolomic analyses in a mouse model of HFpEF showed that levels of indole-3-propionic acid (IPA), a metabolite produced by gut bacteria from tryptophan, were reduced in the plasma and heart tissue of HFpEF mice as compared with controls. We then examined the role of IPA in mouse models of HFpEF as well as 2 human HFpEF cohorts.
resultsThe protective role and therapeutic effects of IPA were confirmed in mouse models of HFpEF using IPA dietary supplementation. IPA attenuated diastolic dysfunction, metabolic remodeling, oxidative stress, inflammation, gut microbiota dysbiosis, and intestinal epithelial barrier damage. In the heart, IPA suppressed the expression of NNMT (nicotinamide N-methyl transferase), restored nicotinamide, NAD
conclusionsOur findings reveal that IPA protects against diastolic dysfunction in HFpEF by enhancing the nicotinamide adenine dinucleotide salvage pathway, suggesting the possibility of therapeutic management by either altering the gut microbiome composition or supplementing the diet with IPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.